1. Home
  2. ONEG vs MRKR Comparison

ONEG vs MRKR Comparison

Compare ONEG & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneConstruction Group Limited Ordinary Shares

ONEG

OneConstruction Group Limited Ordinary Shares

HOLD

Current Price

$10.83

Market Cap

33.3M

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.52

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONEG
MRKR
Founded
2021
1999
Country
Hong Kong
United States
Employees
26
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.3M
27.7M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
ONEG
MRKR
Price
$10.83
$1.52
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.5M
132.2K
Earning Date
01-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.96
$0.81
52 Week High
$13.50
$4.07

Technical Indicators

Market Signals
Indicator
ONEG
MRKR
Relative Strength Index (RSI) 95.74 51.74
Support Level $10.26 $1.34
Resistance Level $12.04 $1.55
Average True Range (ATR) 1.13 0.09
MACD 0.50 -0.01
Stochastic Oscillator 62.71 44.91

Price Performance

Historical Comparison
ONEG
MRKR

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.

Share on Social Networks: